Literature DB >> 15980322

Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.

Mark A Winters1, Thomas C Merigan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15980322      PMCID： PMC1168704          DOI： 10.1128/AAC.49.7.2575-2582.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  67 in total

1.  Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.

Authors:  Santiago Moreno; José L Casado; María J Pérez-Elías; Fernando Dronda; Antonio Antela; Ana Moreno; Carolina Gutiérrez
Journal:  AIDS       Date:  2003-06-13       Impact factor: 4.177

2.  A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.

Authors:  Martin Stürmer; Schlomo Staszewski; Hans W Doerr; Kurt Hertogs
Journal:  AIDS Res Hum Retroviruses       Date:  2003-11       Impact factor: 2.205

3.  Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Authors:  Jeannette M Whitcomb; Wei Huang; Kay Limoli; Ellen Paxinos; Terri Wrin; Gail Skowron; Steven G Deeks; Michael Bates; Nicholas S Hellmann; Christos J Petropoulos
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

4.  The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Authors:  Richard H Haubrich; Carol A Kemper; Nicholas S Hellmann; Philip H Keiser; Mallory D Witt; Donald N Forthal; John Leedom; Matthew Leibowitz; Jeannette M Whitcomb; Douglas Richman; J Allen McCutchan
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

5.  Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.

Authors:  Peter R Meyer; Johan Lennerstrand; Suzanne E Matsuura; Brendan A Larder; Walter A Scott
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

7.  Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Authors:  Valery Fikkert; Bénédicte Van Maele; Jo Vercammen; Anke Hantson; Barbara Van Remoortel; Martine Michiels; Cristina Gurnari; Christophe Pannecouque; Marc De Maeyer; Yves Engelborghs; Erik De Clercq; Zeger Debyser; Myriam Witvrouw
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.

Authors:  Boulbaba Selmi; Jérôme Deval; Joëlle Boretto; Bruno Canard
Journal:  Antivir Ther       Date:  2003-04

9.  Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy.

Authors:  Shiro Ibe; Naomi Shibata; Makoto Utsumi; Tsuguhiro Kaneda
Journal:  Microbiol Immunol       Date:  2003       Impact factor: 1.955

10.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971
View more
  13 in total

1.  HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Annie Aniana; Jane M Sayer; John M Louis; Irene T Weber
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

2.  Evidence for the acquisition of multi-drug resistance in an HIV-1 clinical isolate via human sequence transduction.

Authors:  Yutaka Takebe; Alice Telesnitsky
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

3.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

4.  Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses.

Authors:  Hanh Thi Pham; Said Hassounah; Brandon F Keele; Koen K A Van Rompay; Thibault Mesplède
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

5.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

6.  Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.

Authors:  Klára Grantz Sasková; Milan Kozísek; Pavlína Rezácová; Jirí Brynda; Tatyana Yashina; Ron M Kagan; Jan Konvalinka
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

7.  A novel codon insert in protease of clade B HIV type 1.

Authors:  Parris S Jordan; Art Poon; Joseph Eron; Kathleen Squires; Caroline Ignacio; Douglas D Richman; Davey M Smith
Journal:  AIDS Res Hum Retroviruses       Date:  2009-05       Impact factor: 2.205

8.  Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.

Authors:  Milan Kozísek; Klára Grantz Sasková; Pavlína Rezácová; Jirí Brynda; Noortje M van Maarseveen; Dorien De Jong; Charles A Boucher; Ron M Kagan; Monique Nijhuis; Jan Konvalinka
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

9.  GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

Authors:  Klára Grantz Šašková; Milan Kozíšek; Kirsten Stray; Dorien de Jong; Pavlína Rezáová; Jirí Brynda; Noortje M van Maarseveen; Monique Nijhuis; Tomáš Cihlár; Jan Konvalinka
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

Review 10.  The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.

Authors:  Adewunmi Onafuwa-Nuga; Alice Telesnitsky
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.